About

ABOUT

Instil Bio, Inc is a global, clinical-stage cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of cancer. We are building on the decades-long foundation of TIL efficacy in treating solid tumors, applying our cell therapy experience and TIL manufacturing platform to bring the promise of TIL therapy to patients in need.

Instil Bio has research and cell therapy manufacturing facilities in Los Angeles, CA and Manchester, UK, with corporate offices in Dallas, TX.

Our Executives

Bronson Crouch
Chief Executive Officer

Mr. Crouch is an entrepreneur and investor with over 15 years of experience in the biotechnology and pharmaceutical industry. Mr. Crouch is currently the Managing Partner of Curative Ventures, a private equity investment firm focused on biopharma opportunities. Key investments in the recent past include CoStim Pharmaceuticals, Inc., an immuno-oncology-focused biotech company (acquired by Novartis in 2014), TCR2 Therapeutics, Inc. (Nasdaq: TCRR), a cell therapy company, Peloton Therapeutics, Inc., an oncology biotech company focused on renal cell cancer (acquired by Merck in 2019 for $1.1 Billion cash upfront) and iTeos Therapeutics, Inc., (Nasdaq: ITOS) an immuno-oncology biotechnology company.

Vijay Chiruvolu, PhD, MBA
Chief Technical Officer

Vijay Chiruvolu, PhD, MBA, is the Chief Technical Officer of Instil Bio responsible for Process Development, Quality, Manufacturing, Supply Chain and Facilities & Engineering. Vijay has extensive technical leadership experience in development and manufacturing of recombinant proteins, monoclonal antibodies, gene and cell therapy products. Most recently, Dr. Chiruvolu was Senior Vice President of Process Development at Kite, a Gilead Company since joining in 2014. During his time at Kite, Dr. Chiruvolu was responsible for the CMC/process development that led to approval of two cell therapy products, Yescarta® and Tecartus®. Prior to joining Kite, Dr. Chiruvolu has spent 18 years in various positions in Process Development, Manufacturing, and Quality with increasing leadership responsibilities at Scios, Avigen, Hoffmann-La Roche, Johnson & Johnson and Amgen. Vijay serves on biotech advisory board of PDA and leads PDA’s process validation and cell & gene therapy interest groups. Vijay holds a PhD (Biochem. Eng.) from University of Nebraska-Lincoln and an MBA in finance and strategy from Penn State’s Smeal College of Business.

Mark Dudley, PhD
Chief Scientific Officer

Mark Dudley, PhD, is the Chief Scientific Officer of Instil Bio. Prior to Instil, Dr. Dudley led early development of T cell therapies at Adaptimmune Therapeutics plc, and before that was on the technical R&D leadership team at Novartis. Before Novartis, Dr. Dudley spent nearly two decades at the Surgery Branch of the National Cancer Institute, where he contributed to a diverse portfolio of experimental T cell therapies, including TIL, TCR-T, and CAR-T products. Dr. Dudley is a recognized pioneer in adoptive cell therapy, having published seminal studies in TIL therapy for refractory melanoma patients, and the first studies of CD19 CAR-T in humans, IL-2 and IL-12 genetically engineered T cells in clinical trials, and TCR-T cells in clinical trials. Dr. Dudley received his PhD in Biological Sciences from Stanford University.

Sandeep “Steve” Laumas, MD
Chief Financial Officer

Dr. Laumas has served as the Chief Financial Officer and Chief Business Officer of Instil Bio since February, 2021 and June 2020, respectively. He began his career at Goldman Sachs & Co. in 1996 in the healthcare investment banking division before transitioning to the healthcare equity research division. He was an analyst at Balyasny Asset Management from 2001-03 and then a Managing Director of North Sound Capital from 2003-07, where he was responsible for the global healthcare investment portfolio. He founded and managed Bearing Circle Capital, an investment partnership, since 2008. Dr. Laumas has served as a member of the board of directors of Bioxcel Therapeutics Inc. since 2017 and a board member of Unicycive Therapeutics Inc. since 2018. He previously served as a board member of 9 Meters Biopharma, Inc. from 2020-21, its Executive Chairman from 2014-20, including its Chief Executive Officer from 2019-20. Dr. Laumas received his A.B. (Chemistry) from Cornell University in 1990, his M.D. from Albany Medical College in 1995, with a research year at the Dana-Farber Cancer Institute and completed his medical internship at the Yale University School of Medicine in 1996.

Sumita Ray, JD
Chief Legal, Compliance, and Administrative Officer

Sumita Ray is the Chief Legal, Compliance, and Administrative Officer of Instil Bio. With more than 20 years of pharmaceutical and biotechnology experience, Ms. Ray brings a breadth of knowledge in FDA regulatory law, global health care law and compliance, brand support, product launches, collaborations and alliances. Prior to joining Instil Bio, Ms. Ray was the Chief Legal and Administrative officer of Calithera Biosciences. Prior to joining Calithera, Ms. Ray served on the Executive Management Team of Pharmacyclics, as Chief Compliance Officer and Associate General Counsel, Head of Healthcare and Regulatory Law, until its acquisition by Abbvie. Prior to Pharmacyclics, she served in leadership roles as in-house counsel for Elan Pharmaceuticals, Genentech and AstraZeneca. Ms. Ray started her career as a pharmaceutical and products liability litigator at Montgomery, McCracken, Walker and Rhoads LLP. Ms. Ray currently serves as a member of the board of directors for Biomea Fusion, and serves on the Advisory Board of BioTrillion. Ms. Ray holds a J.D. from Temple University School of Law and a B.S. in Microbiology from the University of Arizona.

Zachary Roberts, MD, PhD
Chief Medical Officer

Dr. Roberts is a board certified oncologist and immunologist with extensive experience in clinical oncology and oncology drug and cell therapy development.  Prior to joining Instil, Dr. Roberts held various roles of increasing responsibility at Kite Pharma (acquired by Gilead in 2017) where he led the development of both clinical and near-clinical cell therapy assets, established several strategic domestic and international corporate partnerships, and held key scientific advisory and oversight roles within the company.  Before joining Kite, Dr. Roberts led several solid tumor studies at Amgen.  He holds an MD and PhD in immunology from the University of Maryland, Baltimore, where he graduated magna cum laude from both medical and graduate schools.  He went on to complete his clinical and post-doctoral training at Massachusetts General Hospital and the Dana-Farber Cancer Institute.

Our Board of Directors

Bronson Crouch
Chairman of the Board

Mr. Crouch is an entrepreneur and investor with over 15 years of experience in the biotechnology and pharmaceutical industry. Mr. Crouch is currently the Managing Partner of Curative Ventures, a private equity investment firm focused on biopharma opportunities. Key investments in the recent past include CoStim Pharmaceuticals, Inc., an immuno-oncology-focused biotech company (acquired by Novartis in 2014), TCR2 Therapeutics, Inc. (Nasdaq: TCRR), a cell therapy company, Peloton Therapeutics, Inc., an oncology biotech company focused on renal cell cancer (acquired by Merck in 2019 for $1.1 Billion cash upfront) and iTeos Therapeutics, Inc., (Nasdaq: ITOS) an immuno-oncology biotechnology company.

Gwendolyn Binder, PhD
Board Member

Dr. Gwendolyn Binder joined the Instil Board in 2020. Dr. Binder is an R&D executive with specialized expertise in the discovery and early clinical development and optimization of engineered T cell therapies. Currently, Dr. Binder is the E.V.P. of Science and Technology at Cabaletta Bio, which is developing engineered T cells for B cell mediated autoimmune diseases.  From 2011-2018, Dr. Binder established the U.S. arm of and served as Chief Technology Officer (CTO) for Adaptimmune, developing TCR-engineered T-cells for oncology. From 2006-2011, Dr. Binder served as the Director of Translational Research Operations for Carl June at the University of Pennsylvania, where she progressed multiple IND submissions for novel engineered T-cell therapies in HIV and oncology, including the CD19 CAR IND acquired by Novartis (now Kymriah), the first human gene editing IND, and three TCR engineered T cell therapy studies in oncology and HIV. From 2002-2005, Dr. Binder served as the Director of Scientific Affairs at VIRxSYS Corporation in Gaithersburg, Maryland, where she supported the development of the first clinical lentiviral vector used in humans, for the application of engineered T cell therapy for HIV. Dr. Binder studied viral immunology and translational research at the Johns Hopkins University in Baltimore, USA where she earned in Ph.D. in Cellular and Molecular Medicine in 2002.

Neil Gibson, PhD
Board Member

Dr. Gibson, PhD, is an experienced drug developer, having contributed to the successful approval of multiple blockbuster oncology therapeutics, including temozolomide, erlotinib, crizotinib, and sorafenib. Dr. Gibson is currently the CEO of Adanate, an immunotherapy company. Previously, Dr. Gibson has held Chief Scientific Officer roles in multiple pharma and biotech companies, including Regulus Therapeutics, Pfizer Oncology, and OSI Pharmaceuticals. At Pfizer he was a member of the global R&D leadership team as well as a member of the Oncology Business unit leadership team.  He has also held numerous academic appointments, including Associate Professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. Dr. Gibson earned his PhD from the University of Aston, Birmingham, England.

George Matcham, PhD
Board Member

Dr. Matcham had 30 successful years at Celgene Corporation, joining in 1988 soon after the IPO when the company had 30 employees, and retiring in 2018 with the company soon to be valued at $74Billion in the acquisition by BMS. During his time at Celgene, he focused mainly on Biotech Research, Development and Manufacturing and held positions such as COO of Celgene Cellular Therapeutics, SVP of Biologics Development and Manufacturing, and SVP CAR T CMC & Technology Development. In these roles, he led internal technical development and clinical manufacturing and was extensively involved in external programs in Biologics and Cell Therapy development, including co-leading CAR T cell manufacturing in the collaboration with Juno, and representing Celgene on the Sutro Biopharma Board of Directors. Before coming to the USA, Dr. Matcham held academic positions in teaching and research at the University of Cambridge and obtained a PhD in Biochemistry at Cardiff University.

R. Kent McGaughy, Jr.
Board Member

R. Kent McGaughy, Jr. is a founding shareholder of CPMG, Inc.  Prior to joining CPMG’s predecessor, Cardinal Investment Company, in 1997, Mr. McGaughy worked in investment banking at Simmons & Company International.  Mr. McGaughy serves as a Director of Reata Pharmaceuticals (NASDAQ:  RETA), Apollo Endosurgery (NASDAQ:  APEN), Cuda Pharmaceuticals LLC, Waterfall Security Solutions, Ltd. and Instil Bio, Inc. Mr. McGaughy holds a B.A. from The University of Texas (Plan II Honors, Summa Cum Laude, and member of Phi Beta Kappa) and an M.B.A. from Harvard Business School.

Jack B. Nielsen
Board Member

Mr. Nielsen has served as a member of our board of directors since August 2020. Mr. Nielsen has served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm, since August 2017, and previously served as a consultant from March 2017 to July 2017. From 2001 to February 2017, Mr. Nielsen was with the Novo A/S (Novozymes) organization and its venture activities in several roles, most recently as a Senior Partner based in Copenhagen, Denmark. From May 2006 to August 2012, Mr. Nielsen was a Partner at Novo Ventures (US) in San Francisco, where he established the office that provides certain consultancy services to Novo A/S. He currently serves as a member of the board of directors of the public biotech companies Aligos Therapeutics, ALX Oncology, Harmony Biosciences and Reata Pharmaceuticals, and previously served as a director of Akebia Therapeutics, Apollo Endosurgery, Crinetics Pharmaceuticals and Merus, N.V., as well as several private biotech companies. Mr. Nielsen holds an M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology from Center for Technology, Economics and Management, Technical University of Denmark.